Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.
Emergent BioSolutions will buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA-approved needle-free emergency opioid overdose treatment.
The U.S. Justice Department joined several whistleblower lawsuits against Indivior and Reckitt Benckiser Group, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.
The U.S. Food and Drug Administration issued a new draft guidance for the development of novel medicines aimed at the treatment of opioid use disorder.
Indivior Plc notched a legal victory after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker’s best-selling opioid addiction treatment in the United States.
Indivior said a U.S. court expedited a generic rival’s appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker’s blockbuster opioid addiction treatment.
Indivior Plc’s shares jumped more than 33 percent after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker’s bestselling opioid addiction treatment.
DyAnsys Inc. announced that the U.S. Food and Drug Administration cleared the company’s auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.
Very few U.S. adults receive all the preventive health care services recommended for them, reports a new study.
Britain’s Indivior was subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.